Viral News

Covid-19 vaccination: 434,301 people have completed both doses as of Thursday (April 15)

KUALA LUMPUR (Bernama): A total of 434,301 people have received both doses of their vaccine shots under the first phase of the National Covid-19 Immunisation Programme, as of Thursday (April 15).

Health Minister Datuk Seri Dr Adham Baba (pic) said during the same period, 671,589 individuals received their first dose, bringing the total number of Covid-19 vaccine doses administered in the country to 1,105,890.

In an infographic shared on his official Twitter account Friday (April 16), he said the five states with the most recipients administered with the first dose were Selangor with 93,829, followed by Kuala Lumpur (73,266), Sarawak (67,427), Johor (63,295) and Sabah (55,734).

The five states with the highest number of recipients who had completed both doses so far were Selangor with 61,662 individuals, followed by Perak (48,607), Sabah (42,972), Kuala Lumpur (37,962) and Pahang (33,080).

As for the number who have signed up for the immunisation programme, Dr Adham said as of Thursday, a total of 8,834,823 people or 36.4% of the target had registered with Selangor recording the highest number at 2,333,514.

The first phase of the immunisation programme, from February to April, would involve 500,000 frontliners, mainly health workers.

The second phase, to be implemented from April to August this year will involve 9.4 million senior citizens aged 65 and above, as well as vulnerable groups with co-morbidity problems, in addition to persons with disabilities.

The third phase, scheduled from May to Feb 2022, is for individuals aged 18 and above, targetting about 14 million people.

Meanwhile, Health director-general Tan Sri Dr Noor Hisham Abdullah said the Covid-19 infectivity rate or Ro/Rt based on daily cases in the country was 1.17, as of Thursday.

Based on an infographic shared on his Twitter account, Terengganu recorded the highest Rt of 1.49, while Penang recorded the lowest Rt of 0.89. – Bernama

Read More

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker